Table of Content

1. Key Insights

2. Executive Summary of the Hepatitis D Virus (HDV)

3. SWOT Analysis of Hepatitis D Virus (HDV)

4. Hepatitis D Virus (HDV): Market Share (%) Distribution Overview at a Glance: By Country

5. Epidemiology and Market Methodology

6. Hepatitis Delta Virus (HDV): Disease Background and Overview
6.1. Introduction
6.1.1. Signs and Symptoms of HDV
6.1.2. Risk Factors and Causes of HDV
6.1.3. Pathophysiology of HDV
6.1.4. Factors influencing HDV progression
6.1.5. Complications of HDV Infection

7. Diagnosis of Hepatitis D Infection
7.1. Physical exam
7.2. Blood Tests
7.2.1. Antibodies to HDV
7.2.2. HDV RNA
7.2.3. HD-Antigen
7.2.4. IgM Antibody to the Hepatitis B Core Antigen (IgM Anti-HBc)
7.2.5. HDV genotyping
7.3. Imaging Tests
7.4. Liver Biopsy
7.5. Differential diagnosis for HDV

8. Prevention of HDV

9. Epidemiology and Patient Population
9.1. Epidemiology Key Findings
9.2. Assumptions and Rationale: 7MM

10. Epidemiology Scenario: 7MM
10.1. Total Diagnosed Prevalent cases of HDV in the 7MM
10.2. Gender-specific Diagnosed Prevalent Cases of HDV in the 7MM
10.3. Age-specific Diagnosed Prevalent Cases of HDV in the 7MM
10.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in the 7MM
10.5. Treated cases of HDV in the 7MM

11. The United States Epidemiology
11.1. Total Diagnosed Prevalent cases of HDV in the United States
11.2. Gender-specific Diagnosed Prevalent Cases of HDV in the United States
11.3. Age-specific Diagnosed Prevalent Cases of HDV in the United States
11.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in the United States
11.5. Treated cases of HDV in the United States

12. EU-5 Epidemiology
12.1. Germany
12.1.1. Total Diagnosed Prevalent cases of HDV in Germany
12.1.2. Gender-specific Diagnosed Prevalent Cases of HDV in Germany
12.1.3. Age-specific Diagnosed Prevalent Cases of HDV in Germany
12.1.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in Germany
12.1.5. Treated cases of HDV in Germany
12.2. France
12.2.1. Total Diagnosed Prevalent cases of HDV in France
12.2.2. Gender-specific Diagnosed Prevalent Cases of HDV in France
12.2.3. Age-specific Diagnosed Prevalent Cases of HDV in France
12.2.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in France
12.2.5. Treated cases of HDV in France
12.3. Italy
12.3.1. Total Diagnosed Prevalent cases of HDV in Italy
12.3.2. Gender-specific Diagnosed Prevalent Cases of HDV in Italy
12.3.3. Age-specific Diagnosed Prevalent Cases of HDV in Italy
12.3.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in Italy
12.3.5. Treated cases of HDV in Italy
12.4. Spain
12.4.1. Total Diagnosed Prevalent cases of HDV in Spain
12.4.2. Gender-specific Diagnosed Prevalent Cases of HDV in Spain
12.4.3. Age-specific Diagnosed Prevalent Cases of HDV in Spain
12.4.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in Spain
12.4.5. Treated cases of HDV in Spain
12.5. The United Kingdom
12.5.1. Total Diagnosed Prevalent cases of HDV in the United Kingdom
12.5.2. Gender-specific Diagnosed Prevalent Cases of HDV in the United Kingdom
12.5.3. Age-specific Diagnosed Prevalent Cases of HDV in the United Kingdom
12.5.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in the United Kingdom
12.5.5. Treated cases of HDV in the United Kingdom

13. Japan Epidemiology
13.1. Total Diagnosed Prevalent cases of HDV in Japan
13.2. Gender-specific Diagnosed Prevalent Cases of HDV in Japan
13.3. Age-specific Diagnosed Prevalent Cases of HDV in Japan
13.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in Japan
13.5. Treated cases of HDV in Japan

14. Current Treatment Practices: HDV
14.1. Treatment Algorithm of HDV
14.2. Peg IFN _
14.3. Alternative Options
14.4. Liver transplantation

15. Guidelines of HDV
15.1. American Association for the Study of Liver Diseases (AASLD) Treatment Guidelines
15.2. European Association for the Study of the Liver (EASL) Guidelines

16. Unmet Needs

17. Patient Journey of HDV

18. Key Endpoints in HDV Clinical Trials

19. Emerging Therapies
19.1. Hepcludex (Bulevirtide): MYR Pharmaceuticals/Hepatera
19.1.1. Regulatory Milestones
19.1.2. Other Developmental Activities
19.1.3. Pivotal Clinical Trial
19.1.4. Ongoing Current Pipeline Activity
19.2. Lonafarnib: Eiger Biopharmaceuticals
19.2.1. Product Description
19.2.2. Other Developmental Activities
19.2.3. Clinical Development
19.2.4. Safety and Efficacy
19.3. Peginterferon Lambda: Eiger Biopharmaceuticals
19.3.1. Product Description
19.3.2. Other Developmental Activities
19.3.3. Clinical Development
19.3.4. Safety and Efficacy
19.4. JNJ-73763989 (JNJ-3989): Janssen Pharmaceuticals
19.4.1. Product Description
19.4.2. Clinical Development

20. Hepatitis D Virus (HDV): Seven Major Market Analysis
20.1. Key Findings
20.2. Market Outlook: 7MM
21. 7MM Market Size
21.1. Total Market Size of HDV in the 7MM
21.2. Total Market size of HDV by Therapies in the 7MM
22. United States Market Size
22.1. Total Market size of HDV in the United States
23. EU-5 Market Size
23.1. Germany Market Size
23.1.1. Total Market size of HDV in Germany
23.2. France Market Size
23.2.1. Total Market size of HDV in France
23.3. Italy Market Size
23.3.1. Total Market size of HDV in Italy
23.4. Spain Market Size
23.4.1. Total Market size of HDV in Spain
23.5. United Kingdom Market Size
23.5.1. Total Market size of HDV in the United Kingdom
24. Japan Market Size
24.1. Total Market size of HDV in Japan
25. Market Access and Reimbursement of HDV Therapies
25.1. NHS Recommendation about Vaccination programs
25.2. Reimbursement policy of Medicare
25.3. Expanded Access Policy
26. Market Drivers
27. Market Barriers
28. Appendix
28.1. Bibliography
28.2. Report Methodology
29. DelveInsight Capabilities

30. Disclaimer

31. About DelveInsight



List of Figures


Figure 1: HDV SWOT Analysis
Figure 2: Epidemiology and Market Methodology
Figure 3: Progression of HDV Infection
Figure 4: Signs and symptoms of HDV Infection
Figure 5: HBV-HDV Coinfection
Figure 6: HBV-HDV Superinfection
Figure 7: Causes of HDV
Figure 8: Virion structure of HDV
Figure 9: Virus Replication Cycle
Figure 10: Complications of HDV Infection
Figure 11: Diagnostic Algorithm of HDV
Figure 12: Blood Test
Figure 13: Percutaneous liver biopsy
Figure 14: Prevention of HDV
Figure 15: Total Diagnosed Prevalent cases of HDV in the 7MM (2017–2030)
Figure 16: Gender-specific Diagnosed Prevalent Cases of HDV in the 7MM (2017–2030)
Figure 17: Age-specific Diagnosed Prevalent Cases of HDV in the 7MM (2017–2030)
Figure 18: Diagnosed Prevalent Cases of HDV by Impact on Liver in the 7MM (2017–2030)
Figure 19: Treated cases of HDV in the 7MM (2017–2030)
Figure 20: Total Diagnosed Prevalent cases of HDV in the United States (2017–2030)
Figure 21: Gender-specific Diagnosed Prevalent Cases of HDV in the United States (2017–2030)
Figure 22: Age-specific Diagnosed Prevalent Cases of HDV in the United States (2017–2030)
Figure 23: Diagnosed Prevalent Cases of HDV by Impact on Liver in the United States (2017–2030)
Figure 24: Treated cases of HDV in the United States (2017–2030)
Figure 25: Total Diagnosed Prevalent cases of HDV in Germany (2017–2030)
Figure 26: Gender-specific Diagnosed Prevalent Cases of HDV in Germany (2017–2030)
Figure 27:Age-specific Diagnosed Prevalent Cases of HDV in Germany (2017–2030)
Figure 28: Diagnosed Prevalent Cases of HDV by Impact on Liver in Germany (2017–2030)
Figure 29: Treated cases of HDV in Germany (2017–2030)
Figure 30: Total Diagnosed Prevalent cases of HDV in France (2017–2030)
Figure 31: Gender-specific Diagnosed Prevalent Cases of HDV in France (2017–2030)
Figure 32:Age-specific Diagnosed Prevalent Cases of HDV in France (2017–2030)
Figure 33: Diagnosed Prevalent Cases of HDV by Impact on Liver in France (2017–2030)
Figure 34: Treated cases of HDV in France (2017–2030)
Figure 35: Total Diagnosed Prevalent cases of HDV in Italy (2017–2030)
Figure 36: Gender-specific Diagnosed Prevalent Cases of HDV in Italy (2017–2030)
Figure 37: Age-specific Diagnosed Prevalent Cases of HDV in Italy (2017–2030)
Figure 38: Diagnosed Prevalent Cases of HDV by Impact on Liver in Italy (2017–2030)
Figure 39: Treated cases of HDV in Italy (2017–2030)
Figure 40: Total Diagnosed Prevalent cases of HDV in Spain (2017–2030)
Figure 41: Gender-specific Diagnosed Prevalent Cases of HDV in Spain (2017–2030)
Figure 42: Age-specific Diagnosed Prevalent Cases of HDV in Spain (2017–2030)
Figure 43: Diagnosed Prevalent Cases of HDV by Impact on Liver in Spain (2017–2030)
Figure 44: Treated cases of HDV in Spain (2017–2030)
Figure 45: Total Diagnosed Prevalent cases of HDV in the United Kingdom (2017–2030)
Figure 46: Gender-specific Diagnosed Prevalent Cases of HDV in the United Kingdom (2017–2030)
Figure 47: Age-specific Diagnosed Prevalent Cases of HDV in the United Kingdom (2017–2030)
Figure 48: Diagnosed Prevalent Cases of HDV by Impact on Liver in the United Kingdom (2017–2030)
Figure 49: Treated cases of HDV in the United Kingdom (2017–2030)
Figure 50: Total Diagnosed Prevalent cases of HDV in Japan (2017–2030)
Figure 51: Gender-specific Diagnosed Prevalent Cases of HDV in Japan (2017–2030)
Figure 52: Age-specific Diagnosed Prevalent Cases of HDV in Japan (2017–2030)
Figure 53: Diagnosed Prevalent Cases of HDV by Impact on Liver in Japan (2017–2030)
Figure 54: Treated cases of HDV in Japan (2017–2030)
Figure 55: Treatment Algorithm of HDV
Figure 56: Treatment Algorithm of HDV
Figure 57: Unmet Needs for HDV
Figure 58: Mechanism of action
Figure 59: Mechanism of action of Lonafarnib
Figure 60: Mechanism of action of Peginterferon Lambda
Figure 61: Market Size of HDV in the 7MM, in USD Million (2017–2030)
Figure 62: Market Size of HDV in the 7MM by Therapies, in USD Million (2017–2030)
Figure 63: Market Size of HDV in the United States by Therapy, in USD Million (2017–2030)
Figure 64: Market Size of HDV in Germany by Therapies, in USD Million (2017–2030)
Figure 65: Market Size of HDV in France by therapies, in USD Million (2017–2030)
Figure 66: Market Size of HDV in Italy by Therapies, in USD Million (2017–2030)
Figure 67: Market Size of HDV in Spain by therapies, in USD Million (2017–2030)
Figure 68: Market Size of HDV in the United Kingdom by Therapies, in USD Million (2017–2030)
Figure 69: Market Size of HDV in Japan by Therapy, in USD Million (2017–2030)
Figure 70: Market Drivers of HDV
Figure 71: Market Barriers of HDV


List of Tables


Table 1: Summary of the Hepatitis D Virus (HDV) Market, Epidemiology, and Key Events (2017–2030)
Table 2: Summary of diagnostic tests for the evaluation of patients with HDV infection
Table 3: Total Diagnosed Prevalent cases of HDV in the 7MM (2017–2030)
Table 4: Gender-specific Diagnosed Prevalent Cases of HDV in the 7MM (2017–2030)
Table 5: Age-specific Prevalent Cases of HDV in the 7MM (2017–2030)
Table 6: Diagnosed Prevalent Cases of HDV by Impact on Liver in the 7MM (2017–2030)
Table 7: Total Treated cases of HDV in the 7MM (2017–2030)
Table 8: Total Diagnosed Prevalent cases of HDV in the United States (2017–2030)
Table 9: Gender-specific Diagnosed Prevalent Cases of HDV in the United States (2017–2030)
Table 10: Age-specific Prevalent Cases of HDV in the United States (2017–2030)
Table 11: Diagnosed Prevalent Cases of HDV by Impact on Liver in the United States (2017–2030)
Table 12:Total Treated cases of HDV in the United States (2017–2030)
Table 13: Total Diagnosed Prevalent cases of HDV in Germany (2017–2030)
Table 14: Gender-specific Diagnosed Prevalent Cases of HDV in Germany (2017–2030)
Table 15: Age-specific Prevalent Cases of HDV in Germany (2017–2030)
Table 16: Diagnosed Prevalent Cases of HDV by Impact on Liver in Germany (2017–2030)
Table 17: Total Treated cases of HDV in Germany (2017–2030)
Table 18: Total Diagnosed Prevalent cases of HDV in France (2017–2030)
Table 19: Gender-specific Diagnosed Prevalent Cases of HDV in France (2017–2030)
Table 20: Age-specific Prevalent Cases of HDV in France (2017–2030)
Table 21: Diagnosed Prevalent Cases of HDV by Impact on Liver in France (2017–2030)
Table 22: Total Treated cases of HDV in France (2017–2030)
Table 23: Total Diagnosed Prevalent cases of HDV in Italy (2017–2030)
Table 24: Gender-specific Diagnosed Prevalent Cases of HDV in Italy (2017–2030)
Table 25: Age-specific Prevalent Cases of HDV in Italy (2017–2030)
Table 26: Diagnosed Prevalent Cases of HDV by Impact on Liver in Italy (2017–2030)
Table 27: Total Treated cases of HDV in Italy (2017–2030)
Table 28: Total Diagnosed Prevalent cases of HDV in Spain (2017–2030)
Table 29: Gender-specific Diagnosed Prevalent Cases of HDV in Spain (2017–2030)
Table 30: Age-specific Prevalent Cases of HDV in Spain (2017–2030)
Table 31: Diagnosed Prevalent Cases of HDV by Impact on Liver in Spain (2017–2030)
Table 32: Total Treated cases of HDV in Spain (2017–2030)
Table 33: Total Diagnosed Prevalent cases of HDV in the United Kingdom (2017–2030)
Table 34: Gender-specific Diagnosed Prevalent Cases of HDV in the United Kingdom (2017–2030)
Table 35: Age-specific Prevalent Cases of HDV in the United Kingdom (2017–2030)
Table 36: Diagnosed Prevalent Cases of HDV by Impact on Liver in the United Kingdom (2017–2030)
Table 37: Total Treated cases of HDV in the United Kingdom (2017–2030)
Table 38: Total Diagnosed Prevalent cases of HDV in Japan (2017–2030)
Table 39: Gender-specific Diagnosed Prevalent Cases of HDV in Japan (2017–2030)
Table 40: Age-specific Prevalent Cases of HDV in Japan (2017–2030)
Table 41: Diagnosed Prevalent Cases of HDV by Impact on Liver in Japan (2017–2030)
Table 42: Total Treated cases of HDV in Japan (2017–2030)
Table 43: Lonafarnib + Ritonavir, Clinical Trial Description, 2020
Table 44: Peginterferon lambda, Clinical Trial Description, 2020
Table 45 : JNJ-73763989, Clinical Trial Description, 2020
Table 46: 7MM Market Size of HDV, in USD Million (2017–2030)
Table 47: 7MM Market Size of HDV by Therapies, in USD Million (2017–2030)
Table 48: United States Market Size of HDV by Therapies, in USD Million (2017–2030)
Table 49: Germany Market Size of HDV by Therapies, in USD Million (2017–2030)
Table 50: France Market Size of HDV by Therapies, in USD Million (2017–2030)
Table 51: Italy Market Size of HDV by Therapies, in USD Million (2017–2030)
Table 52: Spain Market Size of HDV by Therapies, in USD Million (2017–2030)
Table 53: United Kingdom Market Size of HDV by Therapies, in USD Million (2017–2030)
Table 54: Japan Market Size of HDV by Therapies, in USD Million (2017–2030)